E-Therapeutics PLC
LSE:ETX

Watchlist Manager
E-Therapeutics PLC Logo
E-Therapeutics PLC
LSE:ETX
Watchlist
Price: 9 GBX -6.74%
Market Cap: 52.6m GBX

Wall Street
Price Targets

ETX Price Targets Summary
E-Therapeutics PLC

There are no price targets for ETX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
E-Therapeutics PLC Competitors:
Price Targets
ARMP
Armata Pharmaceuticals Inc
45% Upside
VLA
Valneva SE
54% Upside
TLX
Telix Pharmaceuticals Ltd
144% Upside
VRTX
Vertex Pharmaceuticals Inc
10% Upside
BNTX
BioNTech SE
30% Upside
BMEA
Biomea Fusion Inc
370% Upside
AZT
Arcticzymes Technologies ASA
41% Upside
4587
PeptiDream Inc
86% Upside

Revenue
Forecast

Revenue Estimate
E-Therapeutics PLC

The compound annual growth rate of E-Therapeutics PLC's revenue for the next 1 year is 8%.

N/A
Past Growth
8%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
E-Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Net Income
Forecast

Net Income Estimate
E-Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-58%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ETX's stock price target?
Not Available

ETX doesn't have any price targets made by Wall Street professionals.

What is E-Therapeutics PLC's Revenue forecast?
Projected CAGR
8%

The compound annual growth rate of E-Therapeutics PLC's revenue for the next 1 year is 8%.

Back to Top